What Is Stage 3B Lung Cancer and How Is It Treated?

Stage 3B lung cancer is a locally advanced form of non-small cell lung cancer (NSCLC) in which the tumor has spread to nearby lymph nodes or invaded adjacent structures in the chest but has not reached distant organs like the brain, bones, or liver. Treatment is aimed at cure or long-lasting control, typically built around concurrent chemotherapy and radiation followed by immunotherapy, though the specific plan depends on the tumor’s biology and the patient’s overall health. Roughly one in four people diagnosed at this stage survives five years, a number that has been climbing with newer therapies.

What Makes It Stage 3B

Lung cancer staging uses a system based on three factors: how large and invasive the primary tumor is (the T descriptor), whether cancer has reached nearby lymph nodes and which ones (the N descriptor), and whether it has spread to distant sites (the M descriptor). In stage 3B, there is no distant spread, so the M descriptor is always M0. What pushes a tumor into the 3B category is a specific combination of tumor size and lymph node involvement that signals extensive local disease.

Several combinations qualify. A very large tumor (over seven centimeters, or one that has grown into major structures like the heart, trachea, or great blood vessels) paired with cancer in lymph nodes on the same side of the chest lands at 3B. A smaller tumor can also reach 3B if cancer has spread to lymph nodes on the opposite side of the chest, in the opposite hilum (where the airway and blood vessels enter the lung), or above the collarbone. These distant nodal stations, classified as N3, represent the farthest lymph node reach before a cancer is reclassified as stage 4 with distant metastasis.

The staging system has been revised several times, and the current eighth edition reclassified a meaningful number of patients compared to earlier versions. In one validation study, the shift to the eighth edition resulted in stage migration for about half of all patients evaluated, with survival estimates for stage 3B actually improving under the newer criteria because some previously grouped patients were moved into different stages.

Getting the Diagnosis Right

Accurate staging is the single most important step before treatment begins, because treatment plans for stage 3A, 3B, and 3C differ substantially. Imaging usually starts with a CT scan and a PET scan, which highlights areas of abnormally active metabolism that suggest cancer. But PET scans are not perfect at reading lymph nodes. In a study of stage III patients who underwent both PET scanning and needle biopsy of lymph nodes through the airway (a procedure called EBUS), about a third of patients had at least one lymph node station where the PET result disagreed with the biopsy result, with PET sensitivity and specificity both around 79%.¹ That means relying on PET alone can overestimate or underestimate the extent of lymph node involvement, so tissue sampling is standard practice before finalizing a treatment plan.

Beyond staging, oncologists now recommend molecular testing of the tumor itself, particularly for patients whose cancer is not squamous cell carcinoma. Broad panel-based profiling, ideally through next-generation sequencing, can identify mutations in genes like EGFR and ALK that open the door to targeted drugs.² Testing is also sometimes recommended for patients with squamous tumors if they are younger, have a light smoking history, or quit long ago. These results can change the entire treatment strategy, so getting them back before treatment starts matters.

Concurrent Chemoradiation as the Foundation

For most people with stage 3B disease, the primary treatment is chemotherapy and radiation delivered at the same time, a regimen known as concurrent chemoradiation. The chemotherapy sensitizes cancer cells to the radiation, making the combination more effective than either treatment alone. Common drug pairings include a platinum agent (cisplatin or carboplatin) with a second drug such as paclitaxel, etoposide, or pemetrexed, depending on the tumor’s histology.

Histology influences drug selection more than many patients realize. In trials comparing outcomes by tumor type, patients with nonsquamous histology (which includes adenocarcinoma, the most common subtype) who received pemetrexed had a response rate of 30%, while patients with squamous histology had a response rate closer to 17%.³ This is why pemetrexed-based regimens are typically reserved for nonsquamous tumors, while squamous tumors are more often treated with taxane- or etoposide-based combinations.

Radiation is typically delivered over five to seven weeks at a total dose of around 60 Gy, given in daily fractions. Dose escalation beyond that range has not consistently improved outcomes and can increase side effects. Modern delivery techniques like intensity-modulated radiation therapy (IMRT) shape the radiation beam more precisely around the tumor, which reduces exposure to healthy lung tissue and the heart. This precision matters for quality of life: patients treated with IMRT have shown less decline in physical well-being and lung-cancer-specific symptoms compared to those treated with older three-dimensional planning techniques.

Immunotherapy After Chemoradiation

The most significant treatment advance for unresectable stage III lung cancer in recent years is the addition of durvalumab, an immunotherapy drug, after chemoradiation is complete. The landmark PACIFIC trial established this approach. Patients whose cancer had not progressed after chemoradiation were randomly assigned to receive durvalumab or a placebo for up to 12 months. The results were striking: median time before the cancer worsened was about 17 months with durvalumab compared to roughly 6 months with placebo.⁴

Five-year follow-up data confirmed the benefit held over time. Estimated five-year overall survival was about 43% in the durvalumab group versus 33% with placebo, and the median overall survival was roughly 47.5 months with durvalumab compared to 29 months without it.⁵ Those numbers represent a genuine shift in what is achievable for a disease that historically had grim five-year statistics. Durvalumab works by blocking a protein called PD-L1 that tumors use to hide from the immune system. By removing that shield after chemoradiation has already damaged the tumor, the immune system gets a better shot at cleaning up remaining cancer cells.

Not every patient qualifies. You need to have completed chemoradiation without your cancer progressing, and you need to be well enough to tolerate the immunotherapy. Common side effects include fatigue, cough, and inflammation of the lungs (pneumonitis), though severe immune-related reactions affect a minority of patients.

Targeted Therapy for Driver Mutations

For the subset of stage 3B patients whose tumors carry certain genetic mutations, targeted drugs are now entering the picture as consolidation therapy after chemoradiation, similar to the role durvalumab plays for other patients. The LAURA and POLESTAR trials established that for tumors with sensitive EGFR mutations, consolidation therapy with osimertinib or aumolertinib after chemoradiation can substantially extend the time before cancer returns.⁶ This is why getting molecular testing done upfront is so important: without knowing whether an EGFR mutation is present, your oncologist would default to immunotherapy consolidation, which is not the best choice for these tumors.

EGFR mutations are more common in certain populations, including people who have never smoked, women, and those of East Asian descent, but they can appear in anyone. ALK rearrangements are another targetable alteration being studied in this setting. The therapeutic landscape here is moving fast, with multiple clinical trials exploring whether other targeted agents can improve outcomes for patients with driver mutations who are not candidates for surgery.

When Surgery Becomes a Possibility

Stage 3B tumors are generally classified as unresectable, meaning surgery alone is not expected to remove the cancer completely. The involvement of lymph nodes across the chest or invasion into critical structures makes a clean surgical margin difficult or impossible. That said, “unresectable” is not always permanent. In selected patients, treatment with chemotherapy and immunotherapy before surgery (neoadjuvant therapy) can shrink the tumor enough that an operation becomes feasible.

A case report illustrates this possibility. A patient with stage 3B squamous cell lung cancer, staged as T3N2M0, had a 6.6 cm centrally located tumor with bulky lymph node disease that was initially deemed unresectable. After three cycles of neoadjuvant pembrolizumab plus chemotherapy, the tumor was successfully resected.⁷ This is a single case, and it involved unusual anatomy that makes generalization tricky, but it reflects a growing trend in thoracic oncology: using immunotherapy-chemotherapy combinations upfront to convert borderline or unresectable tumors into surgical candidates. Large clinical trials are exploring this approach more rigorously.

Managing Treatment Side Effects

Concurrent chemoradiation is effective but hard on the body. The most common serious side effects include drops in white blood cell counts, inflammation of the esophagus (which makes swallowing painful), and radiation pneumonitis, an inflammatory reaction in the lungs. In one early trial using paclitaxel and cisplatin with radiation, pneumonitis affected 30% of patients and significant drops in white blood cell counts occurred in over 40% during the chemoradiation phase.⁸

Radiation pneumonitis risk depends on how much lung tissue receives radiation. A mean lung dose of 12 Gy or higher was identified as a significant risk factor for clinically meaningful pneumonitis in one study, and patients with pre-existing lung scarring (interstitial lung disease) were at particularly elevated risk when a larger portion of their lungs was exposed.⁹ Your radiation oncologist will carefully plan the treatment fields to minimize healthy lung exposure, and if you have known lung disease, that information can influence the plan.

The heart is another organ at risk. When the tumor is on the left side or near central structures, the heart inevitably receives some radiation dose. A pooled analysis of dose-escalation trials at higher-than-standard radiation doses flagged cardiac toxicity as a concern, prompting closer attention to heart dose in modern treatment planning.¹⁰ If you have existing heart disease, your care team should factor that into both the radiation plan and your overall monitoring schedule.

What Drives Prognosis

Five-year overall survival for stage 3B NSCLC sits at roughly 26% when looking at the full population, compared to about 36% for stage 3A and 13% for stage 3C.¹¹ Those figures reflect averages across all treatment approaches and all patients. Individual outcomes vary widely based on several factors.

In a study focused specifically on stage III patients, age, substage, the type of treatment received, and the radiation dose all emerged as independent predictors of survival.¹² Younger patients and those who received combined-modality treatment (chemoradiation rather than radiation alone) had better outcomes. Higher radiation doses, up to the standard range, were also associated with longer survival. Performance status, which is a clinical shorthand for how well you are functioning day to day, consistently predicts outcomes across studies even though it is not always captured in staging data.

The PACIFIC trial results suggest that patients who receive durvalumab consolidation after chemoradiation have five-year survival rates closer to 43%, which is substantially higher than historical averages for stage III as a whole.⁵ This number blends stage 3A, 3B, and 3C patients together, but it signals that the 26% figure for 3B will likely improve as durvalumab and targeted consolidation agents become standard practice.

Follow-Up After Treatment

Recurrence is common after treatment for locally advanced lung cancer. In a large study of surgically treated stage IIIA patients, over half developed recurrences, and the majority of those were at distant sites rather than local ones.¹³ The risk is highest in the first two years after treatment but remains meaningful through at least year four. For stage 3B patients treated with chemoradiation rather than surgery, recurrence rates are at least as high, which makes a structured surveillance plan essential.

Guidelines from a major oncology organization recommend surveillance imaging with CT scans every six months for the first two years after curative-intent treatment, then annually afterward to watch for both recurrence and new primary lung cancers.¹⁴ PET scans are not recommended for routine surveillance. Blood-based biomarkers, while an active area of research, are also not yet ready for standard follow-up use.

There is a practical question many patients ask: does catching a recurrence early on a scan actually help compared to waiting until symptoms appear? The evidence is mixed. One study found that routine CT surveillance detected more localized recurrences than symptom-driven follow-up, but overall survival did not differ between the two groups.¹⁵ This likely reflects the fact that even when recurrence is found early, treatment options for recurrent disease remain limited, though newer therapies are gradually expanding what is possible at that point.

The Cost of Newer Treatments

Durvalumab consolidation adds a year of immunotherapy to an already expensive treatment course, which raises questions about affordability and access. Cost-effectiveness analyses have examined this from multiple angles. In the United States, the incremental cost per quality-adjusted life year gained with durvalumab ranged from roughly $60,000 to $146,000 across different analyses, and in European countries the range was about $62,000 to $76,000.¹⁶ These figures generally fell below the willingness-to-pay thresholds used in each country to decide whether a treatment is worth funding, which is part of why durvalumab has been approved and reimbursed in many healthcare systems.

An updated analysis using longer-term PACIFIC data estimated that durvalumab added about one additional quality-adjusted life year per patient at a cost of roughly $139,000 per quality-adjusted year in the U.S. context.¹⁷ Whether that feels like a reasonable price depends heavily on the healthcare system and insurance coverage involved. International analyses have argued for value-based pricing models that adjust the drug’s cost to each country’s economic reality, to avoid creating access gaps in lower-income settings.¹⁸

How Staging Revisions Affect What 3B Means

If you look up survival statistics for stage 3B, you might find numbers that seem inconsistent across different sources. Part of the reason is that the definition of 3B has shifted with each revision of the TNM staging system. The transition from the seventh edition to the current eighth edition reclassified a large share of patients, with the rate of stage migration reaching about 50% and nearly all of those being upstaged to a higher category.¹⁹ One consequence is that stage 3B survival rates actually looked better after the eighth edition was adopted, not because treatment improved overnight, but because the patients now classified as 3B were a slightly different group than those classified as 3B under the older system.

This matters if you are comparing your situation to studies published before 2018 or reading survival statistics from different time periods. A “stage 3B” from a study using the seventh edition may not be the same disease as a “stage 3B” under the eighth edition. Your oncologist will be staging your cancer using the current system, but older data in the published literature uses prior definitions. Keep that in mind when you encounter survival numbers that seem higher or lower than what your care team quotes.